Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes.
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Moxonidine (Primary)
- Indications Metabolic syndrome; Polycystic ovary syndrome
- Focus Therapeutic Use
- 12 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Dec 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 20 Dec 2013 Status changed from not yet recruiting to recruiting as reported by Clinicaltrials.gov